Skip to content
stoqly
en

Popular

All languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

Akso Health Group

AHG Nasdaq Services-Business Services, Nec Financials FY2017โ€“FY2026

Last close ยท Oct 23, 2026

$1.30

6.6%
Compare
Revenue Total sales reported in the income statement.
$13.8M
6.4% vs prior year
Operating margin Operating income as a share of revenue.
โˆ’149.7%
975.7ย pts
Net income Profit after all expenses, interest and tax.
โˆ’$18.7M
Free cash flow Cash from operations minus capital spending.
โˆ’$12.8M
1,350.9%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ€”
Market cap Last close times the latest diluted share count, so it is approximate.
$940M
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
43.3x
On $0.03 EPS (TTM)

What Akso Health Group does

No business description yet.

Legal name
Akso Health Group
Fiscal year ends
March 31, 2026
Latest annual report
20-F ยท Jul 23, 2026
Accession ยท CIK
0001213900-26-080868
0001702318

Revenue and margins

Akso Health Group had $13.8M of revenue in fiscal 2026, down 6.4% on the year before.

Revenue
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

From fiscal 2017 to 2026, diluted EPS grew โˆ’28.3% a year. Loss periods are shown in red.

Net income
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was โˆ’$12.8M in fiscal 2026, โˆ’92.5% of revenue. Cash from operations minus capital spending.

Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Akso Health Group returned โ€” to shareholders in fiscal 2026. The diluted share count rose 153.5%.

Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Akso Health Group can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY22FY23FY24FY25FY26
Cash and short-term investments $18.4M$7.9M$85.2M$176M$0.2M
Interest coverage โˆ’4.1xโ€”โ€”โ€”โ€”
Current ratio 1.2x1.8x39.5x14.2x21.8x
Quick ratio 1.1x1.6x39.5x14.2x21.7x
Total assets $62.8M$20.5M$142M$215M$190M
Total liabilities $50.5M$11.6M$3.6M$15.8M$8.7M
Shareholders' equity $12.3M$8.7M$138M$199M$181M
Net debt (โˆ’ = net cash) โ€”โ€”โ€”โ€”โ€”

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โ€œPlanโ€ marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

โ€”

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8โ€“9 is strong, 0โ€“2 weak.

TestFY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Net income is positive โœ“ โœ“ โœ“ โœ• โœ• โœ• โœ• โœ• โœ• โœ•
Cash from operations is positive โœ“ โœ“ โœ• โœ• โœ“ โœ• โœ• โœ“ โœ“ โœ•
Return on assets rose โ€” โœ“ โœ• โœ• โœ“ โœ“ โœ“ โœ• โœ• โœ“
Cash from operations exceeds net income โœ• โœ“ โœ• โœ“ โœ“ โœ“ โœ• โœ“ โœ“ โœ“
Debt fell relative to assets โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€”
Current ratio rose โ€” โ€” โœ• โœ“ โœ• โœ• โœ“ โœ“ โœ• โœ“
Share count didn't rise โ€” โœ• โœ• โœ“ โœ• โœ• โœ• โœ• โœ• โœ•
Gross margin rose โ€” โœ• โœ• โœ“ โœ• โœ• โœ• โœ• โœ• โœ“
Revenue rose relative to assets โ€” โœ• โœ• โœ“ โœ• โœ“ โœ“ โœ• โœ“ โœ“
F-score โ€” / 34 / 71 / 85 / 83 / 83 / 83 / 83 / 83 / 85 / 8
Accruals ratio 1.3%โˆ’23.1%4.3%โˆ’10.2%โˆ’68.4%โˆ’14.5%4.5%โˆ’13.3%โˆ’76.3%โˆ’2.9%
Altman Z'' โ€”16.396.570.720.40โˆ’1.57โˆ’9.7444.9410.5823.59

10 years of figures

Amounts in USD. Hover a ratioโ€™s name for its definition.

Download CSV
Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Income statement
Revenue $22.9M $107M $3.7M $6.9M $1.8M $6.0M $13.2M $2.4M $14.8M $13.8M
Net interest income โ€” $0.6M โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€”
Provision for credit losses โ€” โ€” $1.1M $14.2M $22.2M $5.6M โ€” โ€” โ€” โ€”
Gross profit $22.9M $107M โˆ’$3.7M $6.9M $1.8M $0.6M $1.3M $0.1M โˆ’$0.3M โˆ’$0.0M
Research and development $1.6M $2.8M $0.0M $0.1M $0.4M $0.4M โ€” โ€” โ€” โ€”
Operating income $9.9M $75.9M โˆ’$7.2M โˆ’$48.1M โˆ’$4.2M โˆ’$3.3M โˆ’$14.3M โˆ’$8.6M โˆ’$166M โˆ’$20.7M
Interest expense โ€” โ€” โ€” โ€” $2.2M $0.8M โ€” โ€” โ€” โ€”
Pretax income $10.1M $76.5M โˆ’$6.8M โˆ’$46.9M โˆ’$4.3M โˆ’$4.0M โˆ’$13.1M โˆ’$9.1M โˆ’$166M โˆ’$20.7M
Income tax $1.5M $11.0M $0.8M $0.5M $0.5M $0.1M $0.0M $0.0M โˆ’$30.8M โˆ’$2.0M
Net income $8.6M $65.5M $5.5M โˆ’$71.2M โˆ’$34.8M โˆ’$16.9M โˆ’$1.4M โˆ’$9.5M โˆ’$135M โˆ’$18.7M
Net income to common $8.6M $65.5M $5.5M โˆ’$71.2M โ€” โ€” โ€” โˆ’$9.5M โˆ’$135M โˆ’$18.7M
Diluted EPS $0.60 $4.11 $0.30 โˆ’$4.38 โˆ’$2.13 โˆ’$0.84 โˆ’$0.06 $0.21 $0.48 $0.03
Diluted shares 0.01B 0.02B 0.02B 0.02B 0.02B 0.02B 0.02B 0.05B 0.29B 0.72B
Cash flow
Cash from operations $8.2M $87.7M โˆ’$1.7M โˆ’$58.3M $10.1M โˆ’$8.6M โˆ’$3.3M $1.4M $1.2M โˆ’$12.8M
Capital expenditure $0.3M $0.5M $0.0M $0.2M โ€” $0.0M โ€” โ€” $0.2M $0.0M
Free cash flow $7.9M $87.3M โˆ’$1.7M โˆ’$58.5M โ€” โˆ’$8.6M โ€” โ€” $1.0M โˆ’$12.8M
Depreciation and amortization $0.1M $0.2M $0.0M $0.1M $0.0M $0.0M โ€” โ€” $2.1M $2.4M
Stock-based compensation $0.0M $1.8M $6.6M $0.3M $0.1M $0.4M โ€” โ€” โ€” โ€”
Acquisitions โ€” โ€” โ€” โ€” โ€” โ€” โ€” $56.3M $93.8M โ€”
Share buybacks โ€” โ€” $1.3M $2.7M โ€” โ€” โ€” โ€” โ€” โ€”
Dividends paid โ€” โ€” $19.5M โ€” โ€” โ€” โ€” โ€” โ€” โ€”
Dividends and buybacks โ€” โ€” $20.9M $2.7M โ€” โ€” โ€” โ€” โ€” โ€”
Balance sheet
Cash and short-term investments $19.2M $133M $57.4M $6.7M $15.1M $18.4M $7.9M $85.2M $176M $0.2M
Loans, net โ€” $28.7M $76.4M $26.7M $5.5M โ€” โ€” โ€” โ€” โ€”
Current assets โ€” $163M $97.7M $52.0M $30.1M $62.8M $20.5M $142M $196M $190M
Current liabilities โ€” $23.8M $26.6M $12.4M $14.4M $50.5M $11.6M $3.6M $13.8M $8.7M
Inventory โ€” โ€” โ€” โ€” โ€” $7.8M $1.7M $0.2M $0.2M $0.2M
Property and equipment, net $0.4M $0.8M $1.3M $0.1M $0.1M $0.1M โ€” โ€” $0.0M $0.0M
Goodwill โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” $10.8M โ€”
Intangible assets โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” $7.9M $0.1M
Total assets $28.4M $164M $173M $80.5M $50.7M $62.8M $20.5M $142M $215M $190M
Total liabilities $4.9M $23.8M $46.8M $32.4M $14.4M $50.5M $11.6M $3.6M $15.8M $8.7M
Shareholders' equity $23.5M $140M $127M $48.1M $17.3M $12.3M $8.7M $138M $199M $181M
Margins
Gross margin 100.0% 100.0% โˆ’100.2% 100.0% 100.0% 10.1% 9.6% 5.1% โˆ’1.9% โˆ’0.1%
Operating margin 43.3% 70.7% โˆ’194.6% โˆ’695.7% โˆ’241.7% โˆ’54.3% โˆ’108.2% โˆ’357.8% โˆ’1,125.4% โˆ’149.7%
EBITDA margin 43.7% 70.9% โˆ’194.1% โˆ’694.0% โˆ’240.8% โˆ’54.0% โ€” โ€” โˆ’1,110.8% โˆ’132.5%
Net margin 37.4% 61.1% 149.7% โˆ’1,029.7% โˆ’1,984.6% โˆ’280.9% โˆ’10.3% โˆ’391.8% โˆ’913.4% โˆ’135.0%
FCF margin 34.5% 81.4% โˆ’47.1% โˆ’845.7% โ€” โˆ’143.9% โ€” โ€” 6.9% โˆ’92.5%
Net interest share of revenue โ€” 0.6% โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€”
Returns
Return on capital employed โ€” 54.2% โˆ’4.9% โˆ’70.6% โˆ’11.7% โˆ’26.5% โˆ’161.4% โˆ’6.2% โˆ’82.7% โˆ’11.4%
Return on equity 36.5% 80.1% 4.2% โˆ’81.6% โˆ’106.5% โˆ’114.0% โˆ’12.9% โˆ’12.9% โˆ’80.0% โˆ’9.8%
Return on assets 30.2% 68.1% 3.3% โˆ’56.1% โˆ’53.1% โˆ’29.7% โˆ’3.3% โˆ’11.6% โˆ’75.6% โˆ’9.2%
Return on tangible equity 36.5% 46.8% 4.4% โˆ’148.0% โˆ’201.6% โˆ’137.2% โˆ’15.6% โˆ’6.8% โˆ’74.8% โˆ’10.3%
Growth
Revenue growth โ€” 368.0% โˆ’96.6% 87.1% โˆ’74.6% 241.9% 119.7% โˆ’81.7% 512.1% โˆ’6.4%
Net income growth โ€” 664.0% โˆ’91.6% โˆ’1,386.9% โ€” โ€” โ€” โ€” โ€” โ€”
EPS growth โ€” 585.0% โˆ’92.7% โˆ’1,560.0% โ€” โ€” โ€” โ€” 128.6% โˆ’93.8%
FCF growth โ€” 1,004.4% โˆ’102.0% โ€” โ€” โ€” โ€” โ€” โ€” โˆ’1,350.9%
Share count change โ€” 12.6% 11.0% โˆ’7.9% 0.2% 22.1% 15.1% 106.3% 504.4% 153.5%
Financial health
Interest coverage โ€” โ€” โ€” โ€” โˆ’2.0x โˆ’4.1x โ€” โ€” โ€” โ€”
Current ratio โ€” 6.8x 3.7x 4.2x 2.1x 1.2x 1.8x 39.5x 14.2x 21.8x
Quick ratio โ€” 6.8x 3.7x 4.2x 2.1x 1.1x 1.6x 39.5x 14.2x 21.7x
Provision / loans โ€” โ€” 1.4% 53.3% 403.8% โ€” โ€” โ€” โ€” โ€”
Capital allocation
Capex / revenue 1.3% 0.4% 0.2% 2.9% โ€” 0.1% โ€” โ€” 1.0% 0.0%
Stock comp / revenue 0.0% 1.7% 178.2% 5.0% 3.2% 6.5% โ€” โ€” โ€” โ€”
Quality scores
Piotroski F-score โ€” 4.0 1.0 5.0 3.0 3.0 3.0 3.0 3.0 5.0
Altman Z'' โ€” 16.4 6.6 0.7 0.4 โˆ’1.6 โˆ’9.7 44.9 10.6 23.6
Accruals ratio 1.3% โˆ’23.1% 4.3% โˆ’10.2% โˆ’68.4% โˆ’14.5% 4.5% โˆ’13.3% โˆ’76.3% โˆ’2.9%

Source: SEC EDGAR XBRL filings (CIK 0001702318). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. Per-share figures are per US-listed share (1 ADS = 3 ordinary shares). For information only โ€” not investment advice. Check the original filings before relying on any figure.

โ†‘ โ†“ to move ยท โ†ต to open